The short answer
IGF-1 LR3 holds no marketing authorisation from the MHRA, EMA or FDA. A licensed recombinant human IGF-1 does exist (mecasermin, marketed as Increlex), but that is native rhIGF-1, a different molecule, and its approval extends to LR3 in no respect.
Key facts
- MHRA status
- Not authorised
- EMA status
- Not authorised
- FDA status
- Not approved
- Approved related product
- Mecasermin (Increlex), native rhIGF-1
- WADA
- Prohibited at all times, class S2
- Supply basis here
- Laboratory research only
The position
No regulator has assessed IGF-1 LR3. There is no marketing authorisation anywhere, no registered clinical trial programme, and no route by which a laboratory reagent becomes a medicine. It is supplied for laboratory research only.
The complication unique to this category
An approved IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency. That is a real licensed product with real clinical evidence behind it; Petriczko 2019 and Denaite 2024 both report on its use.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
Why that makes things riskier rather than safer
A nearby approval invites the inference that the unapproved analogue is somehow covered by it. It is not. The approved product is the native 70-residue hormone; LR3 is an 83-residue engineered analogue with deliberately altered binding behaviour. Sharing a family name is the entire extent of the relationship, and treating the approval as transferable is the most consequential error available here.
The prohibited status runs alongside
IGF-1 and its analogues sit in WADA class S2, prohibited at all times. That applies regardless of regulatory status and regardless of whether material is described as being for research.
What is said here
That IGF-1 LR3 is an 83-residue recombinant analogue engineered to reduce IGF binding protein affinity, developed as a cell culture reagent, with almost no primary literature under that name. Not said: that it does anything in any person, or that anything about mecasermin's approval applies to it.
The enforcement context
The MHRA opened investigations into UK retailers making therapeutic claims about unregulated products in April 2026. For a compound that is both unlicensed and prohibited in sport, with an approved relative to be confused with, the margin for imprecise language is narrower here than anywhere else in this catalogue.
Frequently asked questions
Is IGF-1 LR3 approved anywhere?
No. It holds no marketing authorisation from any regulator.
But isn't there an approved IGF-1 product?
Yes: mecasermin, marketed as Increlex. That is native rhIGF-1, a different molecule, and its approval does not extend to LR3.
Does research use change the prohibited status?
No. WADA class S2 applies at all times regardless of how material is described or supplied.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- A Natural Experiment in Absent IGF-1People with growth hormone receptor deficiency produce almost no IGF-1. Laron and Werner report that they do not develop cancer.
- A Strong Rationale That Did Not TranslateThe IGF-1 receptor was pursued as an oncology target on excellent biological grounds. The clinical programmes largely failed, and why is instructive.
- A Regulatory System, Deliberately EvadedIGF binding proteins restrain IGF-1 availability. LR3 exists to escape them. Set against the Laron findings, that is worth stating plainly.
- Two Hormones, One Feedback LoopGrowth hormone acts on the liver, the liver produces IGF-1, and IGF-1 feeds back to suppress growth hormone. Laron syndrome breaks the loop mid-way.
- Two Receptors Close Enough to Form HybridsThe IGF-1 and insulin receptors share structure and can assemble into hybrids containing subunits of both. Selectivity is therefore never absolute.